Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.

ABSTRACT:

Background

Inflammatory bowel disease (IBD) is often managed with anti-tumour necrosis factor-α therapy (anti-TNFα), but treatment efficacy is compromised by high annual rates of loss of response (13%-21% per patient-year).

Aims

To assess whether the incidence of loss of response decreases with longer treatment duration METHODS: This was a multicentre, retrospective cohort study of patients with ulcerative colitis (UC) or Crohn's disease (CD) who received anti-TNFα for at least 4 months between 2011 and 2019. We studied the incidence of loss of response as a function of treatment duration, employing parametric survival modelling. Predictors of loss of response were identified by Cox regression analysis. Secondary outcomes included overall anti-TNFα discontinuation and dose e

SUBMITTER: Schultheiss JPD 

PROVIDER: S-EPMC9292495 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature